Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia

An olmsted county study, 1976-1995

Ruben A. Mesa, Murray N. Silverstein, Steven J. Jacobsen, Peter C. Wollan, Ayalew Tefferi

Research output: Contribution to journalArticle

270 Citations (Scopus)

Abstract

To provide basic information about occurrence and outcome of essential thrombocythemia (ET) and agnogenic myeloid metaplasia (AMM), we used the Rochester Epidemiology Project medical record linkage system for residents of Olmsted County, Minnesota. We identified all residents who were diagnosed with ET or AMM from 1976 to 1995. Community inpatient and outpatient medical records were reviewed to verify the diagnosis of ET or AMM, and patients were followed passively through their medical records to determine the outcome after diagnosis. We identified 39 cases of ET and 21 of AMM, with age- and sex-adjusted incidence rates of 2.53 and 1.46 cases/100,000 population annually, respectively. The respective median ages at diagnosis were 72 and 67 years. The female-to-male ratios were 1.8 and 1.6 for ET and AMM, respectively, and when adjusted for age, there was no difference in risk. The median follow-up period was 62.9 months for ET and 33.2 months for AMM. Five- and 10-year survivals were 74.4% and 61.3%, respectively, for ET and were significantly lower than expected for age-matched controls (P = 0.012). Prognosis was worse for AMM, with a median progression time of 7 months and a 3-year survival of 52.4%. This was significantly worse than for age-matched controls (P < 0.001). This study provides population-based incidence and comparative survival figures in ET and AMM.

Original languageEnglish (US)
Pages (from-to)10-15
Number of pages6
JournalAmerican Journal of Hematology
Volume61
Issue number1
DOIs
StatePublished - 1999

Fingerprint

Essential Thrombocythemia
Primary Myelofibrosis
Survival
Incidence
Population
Medical Records
Medical Record Linkage
Inpatients
Epidemiology
Outpatients

Keywords

  • Agnogenic myeloid metaplasia
  • Epidemiology
  • Essential thrombocythemia
  • Outcome
  • Prognosis

ASJC Scopus subject areas

  • Hematology

Cite this

Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia : An olmsted county study, 1976-1995. / Mesa, Ruben A.; Silverstein, Murray N.; Jacobsen, Steven J.; Wollan, Peter C.; Tefferi, Ayalew.

In: American Journal of Hematology, Vol. 61, No. 1, 1999, p. 10-15.

Research output: Contribution to journalArticle

@article{3a067c8e03cb4100b20f5ea1c2c47a56,
title = "Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An olmsted county study, 1976-1995",
abstract = "To provide basic information about occurrence and outcome of essential thrombocythemia (ET) and agnogenic myeloid metaplasia (AMM), we used the Rochester Epidemiology Project medical record linkage system for residents of Olmsted County, Minnesota. We identified all residents who were diagnosed with ET or AMM from 1976 to 1995. Community inpatient and outpatient medical records were reviewed to verify the diagnosis of ET or AMM, and patients were followed passively through their medical records to determine the outcome after diagnosis. We identified 39 cases of ET and 21 of AMM, with age- and sex-adjusted incidence rates of 2.53 and 1.46 cases/100,000 population annually, respectively. The respective median ages at diagnosis were 72 and 67 years. The female-to-male ratios were 1.8 and 1.6 for ET and AMM, respectively, and when adjusted for age, there was no difference in risk. The median follow-up period was 62.9 months for ET and 33.2 months for AMM. Five- and 10-year survivals were 74.4{\%} and 61.3{\%}, respectively, for ET and were significantly lower than expected for age-matched controls (P = 0.012). Prognosis was worse for AMM, with a median progression time of 7 months and a 3-year survival of 52.4{\%}. This was significantly worse than for age-matched controls (P < 0.001). This study provides population-based incidence and comparative survival figures in ET and AMM.",
keywords = "Agnogenic myeloid metaplasia, Epidemiology, Essential thrombocythemia, Outcome, Prognosis",
author = "Mesa, {Ruben A.} and Silverstein, {Murray N.} and Jacobsen, {Steven J.} and Wollan, {Peter C.} and Ayalew Tefferi",
year = "1999",
doi = "10.1002/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I",
language = "English (US)",
volume = "61",
pages = "10--15",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia

T2 - An olmsted county study, 1976-1995

AU - Mesa, Ruben A.

AU - Silverstein, Murray N.

AU - Jacobsen, Steven J.

AU - Wollan, Peter C.

AU - Tefferi, Ayalew

PY - 1999

Y1 - 1999

N2 - To provide basic information about occurrence and outcome of essential thrombocythemia (ET) and agnogenic myeloid metaplasia (AMM), we used the Rochester Epidemiology Project medical record linkage system for residents of Olmsted County, Minnesota. We identified all residents who were diagnosed with ET or AMM from 1976 to 1995. Community inpatient and outpatient medical records were reviewed to verify the diagnosis of ET or AMM, and patients were followed passively through their medical records to determine the outcome after diagnosis. We identified 39 cases of ET and 21 of AMM, with age- and sex-adjusted incidence rates of 2.53 and 1.46 cases/100,000 population annually, respectively. The respective median ages at diagnosis were 72 and 67 years. The female-to-male ratios were 1.8 and 1.6 for ET and AMM, respectively, and when adjusted for age, there was no difference in risk. The median follow-up period was 62.9 months for ET and 33.2 months for AMM. Five- and 10-year survivals were 74.4% and 61.3%, respectively, for ET and were significantly lower than expected for age-matched controls (P = 0.012). Prognosis was worse for AMM, with a median progression time of 7 months and a 3-year survival of 52.4%. This was significantly worse than for age-matched controls (P < 0.001). This study provides population-based incidence and comparative survival figures in ET and AMM.

AB - To provide basic information about occurrence and outcome of essential thrombocythemia (ET) and agnogenic myeloid metaplasia (AMM), we used the Rochester Epidemiology Project medical record linkage system for residents of Olmsted County, Minnesota. We identified all residents who were diagnosed with ET or AMM from 1976 to 1995. Community inpatient and outpatient medical records were reviewed to verify the diagnosis of ET or AMM, and patients were followed passively through their medical records to determine the outcome after diagnosis. We identified 39 cases of ET and 21 of AMM, with age- and sex-adjusted incidence rates of 2.53 and 1.46 cases/100,000 population annually, respectively. The respective median ages at diagnosis were 72 and 67 years. The female-to-male ratios were 1.8 and 1.6 for ET and AMM, respectively, and when adjusted for age, there was no difference in risk. The median follow-up period was 62.9 months for ET and 33.2 months for AMM. Five- and 10-year survivals were 74.4% and 61.3%, respectively, for ET and were significantly lower than expected for age-matched controls (P = 0.012). Prognosis was worse for AMM, with a median progression time of 7 months and a 3-year survival of 52.4%. This was significantly worse than for age-matched controls (P < 0.001). This study provides population-based incidence and comparative survival figures in ET and AMM.

KW - Agnogenic myeloid metaplasia

KW - Epidemiology

KW - Essential thrombocythemia

KW - Outcome

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=0032916213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032916213&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I

DO - 10.1002/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I

M3 - Article

VL - 61

SP - 10

EP - 15

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -